BNF for Children September 2023 Update

This update contains 4 significant changes, 1 dose change, 1 new preparation, 1 deleted monograph and 2 deleted preparations.

Significant Changes:

• Controlled drugs and drug dependence: updated guidance on prescription requirements for Schedule 2 and 3 Controlled Drugs.
• Drugs that cause hepatotoxicity, drugs with CNS depressant effects, and drugs that increase serum potassium: pharmacodynamic effects drug groups revalidated and updated; see Appendix 1 interactions.
• Drugs that cause sedation: new pharmacodynamic effects drug group; see Appendix 1 interactions.
• Non-steroidal anti-inflammatory drugs: potential risks following prolonged use after 20 weeks of pregnancy [MHRA/CHM advice].

Dose Changes:

• Stiripentol [update to include dosing in children from 1 month old].

New Preparations: Azelair® [azelastine hydrochloride].

Deleted Monographs: Glutaraldehyde.

Deleted Preparations: Aminophylline modified-release tablet; Sodium cromoglicate pressurised inhalation.